CO6270229A2 - Derivados de tiazol fusionados como inhibidores de quinasa - Google Patents

Derivados de tiazol fusionados como inhibidores de quinasa

Info

Publication number
CO6270229A2
CO6270229A2 CO09149835A CO09149835A CO6270229A2 CO 6270229 A2 CO6270229 A2 CO 6270229A2 CO 09149835 A CO09149835 A CO 09149835A CO 09149835 A CO09149835 A CO 09149835A CO 6270229 A2 CO6270229 A2 CO 6270229A2
Authority
CO
Colombia
Prior art keywords
fusionated
derivatives
tiazol
inhibitors
quinasa
Prior art date
Application number
CO09149835A
Other languages
English (en)
Spanish (es)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Crepy
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CO6270229A2 publication Critical patent/CO6270229A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO09149835A 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa CO6270229A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
CO6270229A2 true CO6270229A2 (es) 2011-04-20

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09149835A CO6270229A2 (es) 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa

Country Status (20)

Country Link
US (3) US8242116B2 (enExample)
EP (2) EP2035436B1 (enExample)
CN (1) CN101687885B (enExample)
AT (1) ATE510840T1 (enExample)
AU (1) AU2008269577B2 (enExample)
CA (1) CA2692085C (enExample)
CO (1) CO6270229A2 (enExample)
CY (1) CY1114419T1 (enExample)
DK (1) DK2170906T3 (enExample)
EA (1) EA017187B1 (enExample)
ES (2) ES2365258T3 (enExample)
HR (1) HRP20130523T1 (enExample)
IL (1) IL202659A0 (enExample)
ME (1) ME01592B (enExample)
MX (1) MX2009013740A (enExample)
MY (1) MY148852A (enExample)
PL (1) PL2170906T3 (enExample)
PT (1) PT2170906E (enExample)
RS (1) RS52824B (enExample)
WO (1) WO2008001076A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2278973B1 (en) 2008-04-07 2011-11-02 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
WO2010027002A1 (ja) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
CA2752596A1 (en) 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
CA2755253A1 (en) * 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2010135504A1 (en) 2009-05-20 2010-11-25 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as pi3 kinase inhibitors
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
IN2012DN01325A (enExample) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
KR20120101551A (ko) * 2009-12-18 2012-09-13 얀센 파마슈티카 엔.브이. Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
US9040707B2 (en) 2009-12-18 2015-05-26 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
MX2012014575A (es) 2010-06-15 2013-02-07 Bayer Ip Gmbh Nuevos derivados de arilamida orto-sustituidos.
AR084486A1 (es) 2010-10-01 2013-05-22 Basf Se Compuestos de imina
EP2627181A4 (en) * 2010-10-13 2014-03-19 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
EA201390759A1 (ru) * 2010-11-24 2014-03-31 Экселиксис, Инк. БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
HUE036953T2 (hu) 2011-12-22 2018-08-28 Novartis Ag 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
LT2970132T (lt) 2013-03-14 2021-01-11 Epizyme, Inc. Argininmetiltransferazės inhibitoriai ir jų panaudojimas
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US20160257650A1 (en) * 2013-10-21 2016-09-08 Umicore Ag & Co. Kg Monoarylation of aromatic amines
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
EP3849548A1 (en) 2018-09-13 2021-07-21 Stemline Therapeutics Inc. Methods for treating centronuclear myopathy
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
IL283608B2 (en) * 2019-01-08 2025-06-01 Kyorin Pharmaceutical Co Ltd Co Number 0100 01 01479 15-PGDH inhibitor
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
US20130079330A1 (en) 2013-03-28
EP2170906A1 (en) 2010-04-07
US8710054B2 (en) 2014-04-29
DK2170906T3 (da) 2013-06-24
EA201000038A1 (ru) 2010-06-30
ES2365258T3 (es) 2011-09-27
EP2170906B1 (en) 2013-04-03
ES2416364T3 (es) 2013-07-31
ATE510840T1 (de) 2011-06-15
PT2170906E (pt) 2013-06-25
EA017187B1 (ru) 2012-10-30
MY148852A (en) 2013-06-14
IL202659A0 (en) 2010-06-30
CN101687885B (zh) 2012-08-22
RS52824B (enExample) 2013-10-31
CY1114419T1 (el) 2016-08-31
MX2009013740A (es) 2010-02-01
AU2008269577B2 (en) 2012-12-20
ME01592B (me) 2014-09-20
CA2692085A1 (en) 2008-12-31
WO2008001076A1 (en) 2008-01-03
CA2692085C (en) 2015-10-13
CN101687885A (zh) 2010-03-31
EP2035436B1 (en) 2011-05-25
PL2170906T3 (pl) 2013-08-30
US20110003785A1 (en) 2011-01-06
AU2008269577A1 (en) 2008-12-31
US8338592B2 (en) 2012-12-25
HRP20130523T1 (en) 2013-07-31
US20100137302A1 (en) 2010-06-03
US8242116B2 (en) 2012-08-14
EP2035436A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
CO6270229A2 (es) Derivados de tiazol fusionados como inhibidores de quinasa
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
GB0508471D0 (en) Therapeutic agents
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
NI201800141A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
MX380578B (es) Derivados de imidazol pentaciclicos fusionados.
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
MX2009012595A (es) Derivados de espiroindolinona.
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
BR112013015430A2 (pt) derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
CO6220934A2 (es) Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
EP3851439A4 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
UY32280A (es) DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
DOP2009000289A (es) Derivados de tiazol fusionados como inhibidores de quinasa

Legal Events

Date Code Title Description
FG Application granted